Literature DB >> 6879183

Human macrophages armed with murine immunoglobulin G2a antibodies to tumors destroy human cancer cells.

Z Steplewski, M D Lubeck, H Koprowski.   

Abstract

Macrophages isolated from tumor-bearing patients as well as cultured human monocytes express Fc receptors that cross-react strongly with murine immunoglobulins of the G2a but only slightly or not at all with the G1, G2b, or G3 subclasses. Such macrophages in the presence of murine immunoglobulin G2a monoclonal antibodies to tumors mediated the killing of tumor cells in vitro. These data suggest that monoclonal antibodies of the G2a subclass may be useful in the immunotherapy of human cancer.

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6879183     DOI： 10.1126/science.6879183

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  59 in total

1.  Targeting membrane heat-shock protein 70 (Hsp70) on tumors by cmHsp70.1 antibody.

Authors:  Stefan Stangl; Mathias Gehrmann; Julia Riegger; Kristin Kuhs; Isabelle Riederer; Wolfgang Sievert; Kathrin Hube; Ralph Mocikat; Ralf Dressel; Elisabeth Kremmer; Alan G Pockley; Lars Friedrich; Laszlo Vigh; Arne Skerra; Gabriele Multhoff
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

2.  Plant-derived anti-Lewis Y mAb exhibits biological activities for efficient immunotherapy against human cancer cells.

Authors:  Robert Brodzik; Magdalena Glogowska; Katarzyna Bandurska; Monika Okulicz; Deepali Deka; Kisung Ko; Joke van der Linden; Jeanette H W Leusen; Natalia Pogrebnyak; Maxim Golovkin; Zenon Steplewski; Hilary Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-23       Impact factor: 11.205

3.  Inhibition of antibody-dependent cell-mediated cytolysis of tumor cells by Fc receptor of human cytomegalovirus. Brief report.

Authors:  T Murayama; K Shimokawa; T Furukawa
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

4.  Human leukocytes kill varicella-zoster virus-infected fibroblasts in the presence of murine monoclonal antibodies to virus-specific glycoproteins.

Authors:  M Ito; T Ihara; C Grose; S Starr
Journal:  J Virol       Date:  1985-04       Impact factor: 5.103

5.  Remembrances of Hilary Koprowski from a Surgeon's Perspective.

Authors:  Henry F Sears
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2014-06

6.  In vivo efficacy of monoclonal antibody-drug conjugates of three different subisotypes which bind the human tumor-associated antigen defined by the KS1/4 monoclonal antibody.

Authors:  J J Starling; R S Maciak; N A Hinson; C L Nichols; S L Briggs; B C Laguzza
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

7.  Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors.

Authors:  J H Sampson; L E Crotty; S Lee; G E Archer; D M Ashley; C J Wikstrand; L P Hale; C Small; G Dranoff; A H Friedman; H S Friedman; D D Bigner
Journal:  Proc Natl Acad Sci U S A       Date:  2000-06-20       Impact factor: 11.205

Review 8.  Mechanisms of action of therapeutic antibodies for cancer.

Authors:  J M Redman; E M Hill; D AlDeghaither; L M Weiner
Journal:  Mol Immunol       Date:  2015-04-23       Impact factor: 4.407

9.  Dose-related comparison of antibody-dependent cellular cytotoxicity with chimeric and native murine monoclonal antibody 17-1A. Improved cytolysis of pancreatic cancer cells with chimeric 17-1A.

Authors:  Y Haga; C L Sivinski; D Woo; M A Tempero
Journal:  Int J Pancreatol       Date:  1994-02

Review 10.  Immunotherapy of cancer.

Authors:  Hossein Borghaei; Mitchell R Smith; Kerry S Campbell
Journal:  Eur J Pharmacol       Date:  2009-10-20       Impact factor: 4.432
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.